James Rowe, OD
NPI 1447224985 · Optometrist · Harlingen, TX
Enrolled with Medicare as Practitioner - Optometry · source: CMS PECOS Public Provider Enrollment (2026.04.01)
Provider details
- NPI number
- 1447224985
- Entity type
- Individual
- Primary specialty
- OptometristEye and Vision Services Providers
- Credential
- OD
- Sex
- Male
- Sole proprietor
- Yes
- License
- 3284TG (TX)
Specialties & taxonomies
Eye and Vision Services Providers
Profile Score
A profile completeness & documented-activity index — NOT a quality, outcomes, or patient-satisfaction rating.
- Registry tenure25% of score
20 yrs in NPPES registry
- Profile completeness25% of score
100% of core fields populated
- Practice footprint15% of score
1 documented practice location
- Medicare service volume (vs. specialty peers)25% of score
892 Medicare services, 2024 (ranked within specialty)
- Open Payments transparency10% of score
Has Open Payments disclosures (2024)
Medicare volume is ranked against active providers in the same specialty. Signals a provider has no public data for (e.g. Medicare claims) are left out of the score entirely — never counted as zero — so providers without that data are not penalized. See the full formula and weights in our .
What this provider does (Medicare)
Based on Medicare fee-for-service claims, 2024; not all care is captured.
| Service (HCPCS) | Medicare services | Typical Medicare-allowed (2024) |
|---|---|---|
| Established Patient Office Or Other Outpatient Visit With Moderate Level of Decision Making, If Using Time, 30 Minutes Or More99214 | 258 | $119 |
| Exam of Visual Field With Extended Testing92083 | 161 | $58 |
| Photography of the Retina92250 | 131 | $35 |
| Established Patient Office Or Other Outpatient Visit With Straightforward Medical Decision Making, If Using Time, 10 Minutes Or More99212 | 114 | $52 |
| Established Patient Complete Exam of Visual System92014 | 84 | $119 |
| Measurement of Retinal and Optic Nerve Function92273 | 49 | $118 |
What this provider prescribes (Medicare Part D)
Top drugs by Medicare Part D claim volume, 2024 · 11 distinct drugs on file.
| Drug | Part D claims (2024) | Beneficiaries |
|---|---|---|
| Latanoprost | 365 | 73 |
| Timolol Maleate | 132 | 29 |
| Netarsudil Mesylat/Latanoprostbrand: Rocklatan | 42 | — |
| Netarsudil Mesylatebrand: Rhopressa | 27 | — |
| Travoprost | 19 | — |
| Neomycin/Polymyxin B/Dexamethabrand: Neomycin-Polymyxin-Dexameth | 16 | 14 |
| Dorzolamide Hcl | 14 | — |
Transparency — industry payments
Based on CMS Open Payments, 2024; not all care is captured.
$251 across 2 records (Open Payments 2024)
Open Payments discloses payments and transfers of value (meals, travel, consulting, research, royalties) from drug and device makers to providers. This is a transparency signal, not a verdict — such payments are legal and common, and their presence is neither an endorsement nor a criticism. Source: CMS Open Payments, program year 2024.
Practice location
Mailing address
Registry dates
- Enumerated
- 2006-02-13
- Last updated
- 2022-08-29
- Certified
- 2022-08-29
Source: CMS NPPES Data Dissemination (June 2026). NPI Central is not affiliated with CMS. Data is provided as-is from the public registry.